Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A person is 15 to 65 years of age. A person has had chronic asthma for at least one year~Exclusion Criteria:~* A person is a smoker or has smoked more that a pack a day for more than 10 years before stopping~* A person has other lung disorders such as COPD (chronic obstructive pulmonary disorder)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): montelukast Placebo
- 2 (Type: EXPERIMENTAL): montelukast
- 3 (Type: EXPERIMENTAL): montelukast
- 4 (Type: EXPERIMENTAL): montelukast

Based on this trial design, predict the completion outcome and termination type (if applicable).